Capricor Therapeutics Inc (CAPR)
4.71
-0.05
(-1.05%)
USD |
NASDAQ |
Jun 21, 16:00
4.72
+0.01
(+0.21%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (TTM): 39.89M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 39.89M |
| December 31, 2023 | 36.45M |
| September 30, 2023 | 32.74M |
| June 30, 2023 | 28.22M |
| March 31, 2023 | 24.36M |
| December 31, 2022 | 21.82M |
| September 30, 2022 | 19.85M |
| June 30, 2022 | 16.86M |
| March 31, 2022 | 15.39M |
| December 31, 2021 | 13.57M |
| September 30, 2021 | 12.05M |
| June 30, 2021 | 12.17M |
| March 31, 2021 | 10.60M |
| December 31, 2020 | 8.457M |
| September 30, 2020 | 6.541M |
| June 30, 2020 | 4.769M |
| March 31, 2020 | 4.486M |
| December 31, 2019 | 5.142M |
| September 30, 2019 | 7.162M |
| June 30, 2019 | 9.437M |
| March 31, 2019 | 11.18M |
| December 31, 2018 | 12.07M |
| September 30, 2018 | 11.74M |
| June 30, 2018 | 10.47M |
| March 31, 2018 | 10.21M |
| Date | Value |
|---|---|
| December 31, 2017 | 10.77M |
| September 30, 2017 | 10.91M |
| June 30, 2017 | 13.78M |
| March 31, 2017 | 14.96M |
| December 31, 2016 | 16.04M |
| September 30, 2016 | 16.71M |
| June 30, 2016 | 15.17M |
| March 31, 2016 | 14.29M |
| December 31, 2015 | 13.76M |
| September 30, 2015 | 13.01M |
| June 30, 2015 | 11.78M |
| March 31, 2015 | 10.21M |
| December 31, 2014 | 7.782M |
| September 30, 2014 | 6.882M |
| June 30, 2014 | 5.925M |
| March 31, 2014 | 5.381M |
| December 31, 2013 | 5.197M |
| September 30, 2013 | 5.171M |
| June 30, 2013 | 4.339M |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | 3.98M |
| December 31, 2011 | 4.137M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.486M
Minimum
Mar 2020
39.89M
Maximum
Mar 2024
16.50M
Average
12.87M
Median
Research and Development Expense (TTM) Benchmarks
| Cutera Inc | 19.94M |
| Inovio Pharmaceuticals Inc | 77.41M |
| Stereotaxis Inc | 9.77M |
| Vaxart Inc | 67.53M |
| Allogene Therapeutics Inc | 214.94M |